# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-268122
Filing Date
2025-11-06
Accepted
2025-11-06 08:00:45
Documents
67
Period of Report
2025-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | mura-20250930.htm iXBRL | 10-Q | 2529067
2 | EX-31.1 | mura-ex31_1.htm | EX-31.1 | 18816
3 | EX-31.2 | mura-ex31_2.htm | EX-31.2 | 18867
4 | EX-32.1 | mura-ex32_1.htm | EX-32.1 | 11177
5 | EX-32.2 | mura-ex32_2.htm | EX-32.2 | 11229
| Complete submission text file | 0001193125-25-268122.txt |  | 8239429

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | mura-20250930.xsd | EX-101.SCH | 917314
69 | EXTRACTED XBRL INSTANCE DOCUMENT | mura-20250930_htm.xml | XML | 1356996

Mailing Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380
Business Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380 353 1 905 8020
Mural Oncology plc (Filer) CIK: 0001971543 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41837 | Film No.: 251456248
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)